OPTEL GROUP has launched a new product line, Certa, designed specifically to help hospital and retail pharmacies comply with the requirements of the European Union Falsified Medicines Directive (EU FMD), which comes into effect on February 9, 2019.
Building upon OPTEL’s 28 years of expertise in vision, inspection and traceability, OPTEL offers pharmacies a product that enables them to meet immediate compliance needs, and also includes features intended to enhance their long-term strategic operations.
The ergonomically designed OPTEL Certa performs 2D Data Matrix verification and decommissioning of prescription medications and provides connectivity to the National Medicines Verification System (NMVS) across all countries within the European Union.
-
OPTEL Certa has been developed for ease of operation with an automatic stop function and clear notifications displayed on a user-friendly interface.
-
With its ability to connect to existing pharmacy IT infrastructures through the OPTEL Server, system integration requires minimal assistance from pharmacy IT resources, thus decreasing the amount of operational downtime during installation.
-
The connection to the NMVS through the OPTEL Gateway ensures that the verified Unique Identifiers (UI) are sent safely and securely to and from the national database.
OPTEL Certa was designed to assist pharmacies in making healthcare more efficient by leveraging collected 2D Data Matrix information, enabling simplified report generation processes for numbers of recalled, expired and recommissioned products. This system provides visibility into pharmacy operations and inventory, enabling pharmacists to focus efforts on what truly matters─delivering the highest level of patient care.
